Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AMAG Pharmaceuticals, Inc.    AMAG

AMAG PHARMACEUTICALS, INC.

(AMAG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

AMAG PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
03/04/2020 | 07:09am EDT

Item 2.02. Results of Operations and Financial Condition.

The information in this Item 2.02, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), except as expressly set forth by specific reference in such filing.

On March 4, 2020, AMAG Pharmaceuticals, Inc. ("AMAG") issued a press release announcing its operating results for the quarter and year ended December 31, 2019 and its intention to hold a conference call to discuss AMAG's financial results and provide a business update, including an update on recent corporate developments. A copy of AMAG's press release is furnished herewith as Exhibit 99.1 and a copy of the presentation slides to be used during the conference call is furnished herewith as Exhibit 99.2.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 4, 2020, AMAG also announced that Julie Krop, M.D., AMAG's Executive Vice President and Chief Medical Officer, will be leaving AMAG, effective March 31, 2020. In exchange for her agreeing to provide support and transition services through March 31, 2020, AMAG has agreed to provide Dr. Krop with a lump-sum payment of $288,000, subject to certain conditions, including that Dr. Krop execute an effective release and waiver of claims for the benefit of AMAG, as provided in a separation letter expected to be entered into on or about the date hereof.

The foregoing description of the separation letter is not complete and is qualified in its entirety by reference to the letter, which will be filed as an exhibit to AMAG's Quarterly Report on Form 10-Q for the quarter ending March 31, 2020.

Item 7.01. Regulation FD Disclosure.

The information in this Item 7.01, including Exhibit 99.3 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing.

On March 4, 2020, AMAG issued a press release announcing Dr. Krop's departure and related matters. A copy of AMAG's press release is furnished herewith as Exhibit 99.3.

Item 9.01. Financial Statement and Exhibits.




(d) Exhibits.



Exhibit
No.                                      Description
             Press Release of AMAG Pharmaceuticals, Inc., dated March 4, 2020
  99.1     (furnished herewith)
             Copy of AMAG Pharmaceuticals, Inc.'s presentation slides dated March
  99.2     4, 2020 (furnished herewith)
             Press Release of AMAG Pharmaceuticals, Inc., dated March 4, 2020
  99.3     (furnished herewith)




                                       2

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMAG PHARMACEUTICALS, INC.
05/27AMAG Pharmaceuticals to Participate in Jefferies Virtual Global Healthcare Co..
GL
05/22AMAG PHARMACEUTICALS : Completes sale of its rights to intrarosa to millicent ph..
AQ
05/22AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regulat..
AQ
05/21AMAG Pharmaceuticals Completes Sale of its Rights to Intrarosa® to Millicent ..
GL
05/11AMAG PHARMACEUTICALS : 1Q Earnings Snapshot
AQ
05/11AMAG PHARMACEUTICALS, INC. MANAGEME : (form 10-Q)
AQ
05/11AMAG PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Cost..
AQ
05/11AMAG Pharmaceuticals Announces First Quarter 2020 Financial Results and Provi..
GL
04/28AMAG PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regulati..
AQ
04/28AMAG Pharmaceuticals Appoints Scott Myers as President and Chief Executive Of..
GL
More news
Financials (USD)
Sales 2020 250 M
EBIT 2020 -8,07 M
Net income 2020 -31,7 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -7,25x
P/E ratio 2021 -32,2x
Capi. / Sales2020 1,14x
Capi. / Sales2021 1,16x
Capitalization 285 M
Chart AMAG PHARMACEUTICALS, INC.
Duration : Period :
AMAG Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMAG PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 8,22 $
Last Close Price 8,32 $
Spread / Highest target 20,2%
Spread / Average Target -1,22%
Spread / Lowest Target -39,9%
EPS Revisions
Managers
NameTitle
Scott D. Myers President, Chief Executive Officer & Director
Gino Santini Chairman
Edward H. Myles COO, Chief Financial Officer, Treasurer & EVP
Brian Robinson Senior Vice President-Medical Affairs
Robert J. Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMAG PHARMACEUTICALS, INC.-31.64%285
JOHNSON & JOHNSON-0.67%380 857
ROCHE HOLDING AG9.63%302 928
PFIZER, INC.-4.52%208 251
MERCK & CO., INC.-14.73%195 012
NOVARTIS AG-10.47%187 475